Medicare GLP-1 Bridge Program Explained

Starting July 1st, Medicare’s new GLP-1 Bridge program offers eligible beneficiaries access to weight-loss drugs like Wegovy and Zepbound for just $50 a month — a historic step toward tackling the obesity epidemic. Designed as a temporary two-year pilot through 2027, it targets those without existing medical coverage for these meds under Part D, requiring a doctor’s prescription and prior authorization. Participants must meet BMI thresholds and certain health conditions, with higher BMIs needing fewer additional diagnoses. Advocates hail it as a breakthrough for public health, while CMS implements safeguards to prevent misuse — though exact costs and long-term plans remain undisclosed. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a8c46fb18a05c651